• Home
  • R&D


OliX Pipeline

  • Pipeline
  • OLX101A
  • OLX104C
  • OLX301A
  • OLX301D
  • OLX702A
  • OLX703A


MASH Treatment

OliX’s robust metabolic dysfunction-associated steatohepatitis (MASH) program, OLX702A, targets a gene stemming from genome-wide association studies (GWAS). In addition to improving the fatty liver, hepatic steatosis, and fibrosis, OliX is expanding the drug indication to obesity. MASH is the most common liver disease worldwide with no treatment, giving it promising market potential.

* GWAS: This is a study analyzing the correlation between the specific disease and the nucleic sequence, conducted on a large-scale population of 450,000 individuals. It provides statistically significant genetic data.

Target RNA: Undisclosed

Administration Route: Subcutaneous Injection

Metabolic Dysfunction-associated Steatohepatitis (MASH)

MASH is a liver condition characterized by the accumulation of liver fat, inflammation, and hepatocellular damage, regardless of heavy alcohol use. If left untreated, the condition can aggravate to cause fibrosis, cirrhosis, and even liver cancer. MASH often coexists with other metabolic disorders such as obesity, diabetes, and dyslipidemia. While liver fibrosis was considered irreversible, recent studies suggest that robust therapeutics may revert fibrous tissues to normal.

Preclinical Data

Development Status

  • Excellent efficacy in MASH/Fibrosis mouse model
  • Efficacy verified in MASH NHP model
  • Phase 1 clinical trial in progress (AU)
  • Title Link
    A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple- Ascending Dose Study to Evaluate the Safety and Tolerability of OLX75016 in Healthy Volunteers. Learn More

Conference Presentation

  • 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)
  • 2022 Smi RNA Therapeutics Conference (22.02)
  • 2022 OPT (Oligonucleotide & Precision Therapeutics) Congress (22.03)
  • 2023 OPT (Oligonucleotide & Precision Therapeutics) Congress (23.03)
  • 2023 RNAi-Based Therapeutics Summit (23.03)
  • 2023 TIDES USA (23.05)
  • 2023 OTS (Oligonucleotide Therapeutics Society) (23.10)
  • 2023 Obesity & NASH Drug Development Summit (23.11)